Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Buggisch

Showing results (21-30 of 110) with videos related to

Pageof 11
Sort By:
Antiviral Therapy|June 27, 2007
Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis CJohannes Wiegand, Markus Cornberg, Nuray Aslan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 30, 2026
Resolved HBV Infection Is Not Associated With Liver-Related Outcomes in Survival Analysis of Caucasians After HCV CureLaura Muana Wilhelm, Albrecht Stoehr, Peter Buggisch, et al.
Substance Abuse : Research and Treatment|April 5, 2019
Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy-Data From the German Hepatitis C-Registry (DHC-R)Stefan Christensen, Peter Buggisch, Stefan Mauss, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 21, 2015
Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infectionMalte H Wehmeyer, Sabine Jordan, Stefan Lüth, et al.
Addiction (Abingdon, England)|January 24, 2018
Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?Stefan Christensen, Peter Buggisch, Stefan Mauss, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 19, 2016
Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trialsFrank Tacke, Rainer Günther, Peter Buggisch, et al.
Virology Journal|January 31, 2018
A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infectionFabien Zoulim, Christophe Moreno, Samuel S Lee, et al.
Journal of Hepatology|September 3, 2011
Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antiviralsPatrice Cacoub, Marc Bourlière, Jann Lübbe, et al.
Zeitschrift Fur Gastroenterologie|March 8, 2021
[Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries]Karl-Georg Simon, Yvonne Serfert, Peter Buggisch, et al.
Hepatology (Baltimore, Md.)|January 28, 2006
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II studyJohannes Wiegand, Peter Buggisch, Wulf Boecher, et al.
Pageof 11

Showing results (21-30 of 110) with videos related to

Sort By:
Pageof 11
Antiviral Therapy|June 27, 2007
Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis CJohannes Wiegand, Markus Cornberg, Nuray Aslan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 30, 2026
Resolved HBV Infection Is Not Associated With Liver-Related Outcomes in Survival Analysis of Caucasians After HCV CureLaura Muana Wilhelm, Albrecht Stoehr, Peter Buggisch, et al.
Substance Abuse : Research and Treatment|April 5, 2019
Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy-Data From the German Hepatitis C-Registry (DHC-R)Stefan Christensen, Peter Buggisch, Stefan Mauss, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 21, 2015
Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infectionMalte H Wehmeyer, Sabine Jordan, Stefan Lüth, et al.
Addiction (Abingdon, England)|January 24, 2018
Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?Stefan Christensen, Peter Buggisch, Stefan Mauss, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 19, 2016
Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trialsFrank Tacke, Rainer Günther, Peter Buggisch, et al.
Virology Journal|January 31, 2018
A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infectionFabien Zoulim, Christophe Moreno, Samuel S Lee, et al.
Journal of Hepatology|September 3, 2011
Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antiviralsPatrice Cacoub, Marc Bourlière, Jann Lübbe, et al.
Zeitschrift Fur Gastroenterologie|March 8, 2021
[Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries]Karl-Georg Simon, Yvonne Serfert, Peter Buggisch, et al.
Hepatology (Baltimore, Md.)|January 28, 2006
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II studyJohannes Wiegand, Peter Buggisch, Wulf Boecher, et al.
Pageof 11